August 28, 2026 — RNews

#cardiovascular — Friday, August 28, 2026 (1 items)

hot top new

← prev day next day →

0

Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. (linkinghub.elsevier.com)

Sarraju A … Nissen SE The Lancet 2026-08-28

#clinical trial #rnai #therapeutics #cardiovascular #lipidomics